

CERTIFICATE OF FILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being filed with the USPTO electronically via EFS-Web or via first class mail addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below

Date: October 6, 2010

By /Jennifer Archer/
Jennifer Archer

Docket No. 106985-4 KGB
Confirmation No. 8817

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Alexander STEINKASSERER
SERIAL NO. : 10/535,522
CUSTOMER NO. : 27384
FILED : April 13, 2006
FOR : USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS
ENCODING THEM FOR THE TREATMENT OR PREVENTION
OF DISEASES
ART UNIT : 1644
EXAMINER : Amy E. Juedes

October 6, 2010

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed after the mailing of a final office action or a notice of allowance, but on or before the payment of the issue fee. Pursuant to 37 CFR § 1.97(d), consideration of this information disclosure statement requires a petition, which

Applicants hereby request, and payment of the petition fee, which is set forth in 37 CFR § 1.17(i), and which the Commissioner is hereby authorized to charge to Deposit Account No. 14-1263. Consideration of this information disclosure statement also requires a statement under 37 CFR § 1.97(e):

Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO Form SB 08 are being supplied. Copies of U.S. patents are not included pursuant to 37 CFR § 1.98 (a) (2) (ii).

III. Concise Statement of Relevance

All references listed on the attached Form PTO Form SB 08 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By /Kurt G. Briscoe/

Kurt G. Briscoe
Attorney for Applicant(s)
Reg. No. 33,141
875 Third Avenue - 8th Floor
New York, New York 10022
Phone: (212) 808-0700
Fax: (212) 808-0844